Side-by-side earnings comparison across financial stats, AI summaries, management guidance, risks, quotes, and accountability signals.
Piramal Pharma reported a transitional FY26 with revenue decline due to inventory destocking in a key on-patent commercial product, subdued biotech funding in H1, and intensified competition in inhalation anesthesia in non-US markets.
Read Piramal Pharma analysis →Metropolis Healthcare delivered a strong FY26 with group revenue of ₹1,646 crore (+23.6% YoY) and EBITDA margin of 24.4%.
Read Metropolis Healthcare analysis →Piramal Pharma reported a transitional FY26 with revenue decline due to inventory destocking in a key on-patent commercial product, subdued biotech funding in H1, and intensified competition in inhalation anesthesia in non-US markets. However, excluding the destocking impact, underlying business showed modest growth. CDMO saw strong RFP and order inflow recovery in H2, with win rates improving. Consumer healthcare grew 17% in Q4 and 17% for the full year, with power brands up 24%. The company guided for early-to-mid teens revenue growth in FY27, with EBITDA growing faster, excluding the destocked product. Risks include prolonged Middle East tensions causing cost escalations, tariff uncertainties, and the lumpy nature of CDMO revenue skewing to H2.
Metropolis Healthcare delivered a strong FY26 with group revenue of ₹1,646 crore (+23.6% YoY) and EBITDA margin of 24.4%. Organic revenue grew 13.7% YoY, exceeding the 12-13% guidance, driven by patient volume growth of 7.5% and realization improvement. Organic EBITDA margin expanded 140 bps to 25.9%, aided by lab platform upgrades, vendor consolidation, and operating leverage. The core diagnostics acquisition achieved high single-digit EBITDA margin within four quarters, on track for 20%+ in three years. Management guided for 14-15% organic revenue growth and 27-28% group EBITDA margin over the next three years, supported by network productivity gains, specialty mix improvement, and digital channel expansion. Key risks include competitive intensity in tier-1 cities and potential integration challenges from future M&A.
CDMO revenue for Q4 FY26 was ₹1,178 crore; full year ₹4,915 crore.
Consumer healthcare grew 17% in Q4 and full year, driven by power brands and e-commerce.
Market share in US inhalation anesthesia increased from 45% to 47%.
Achieved NPS of 60, surpassing industry average, reflecting high customer satisfaction.
Organic patient volume grew 9.3% in Q4 FY26, driven by network expansion and demand.
Revenue per patient improved ~5% YoY in Q4, driven by specialty and wellness mix.
Digital channels now contribute 25% of revenue, up from 0% three years ago.
Improved from 20:1 to 24:1, targeting 35:1 over three years.
Management expects consolidated revenue growth in the early-to-mid teens for FY27, excluding the previously destocked on-patent commercial product.
Management guidance revenueEBITDA is expected to grow faster than revenue, supported by operating leverage from higher scale.
Management guidance marginsCapital expenditure for FY27 is guided at $120-135 million, primarily for Lexington expansion and other growth projects.
Management guidance capexNet debt to EBITDA is expected to remain range-bound at about 3.6x for FY27, with long-term target of 1x.
Management guidance otherDriven by 8-9% patient volume growth and ~5% realization improvement, with potential price increases.
Management guidance revenueSupported by operating leverage, productivity gains, and core diagnostics reaching 20%+ margin.
Management guidance marginsManagement expects EBITDA margin expansion of 125-150 bps in the coming fiscal year.
Management guidance marginsExpand asset-light network and upgrade centers to include basic radiology, targeting center-to-lab ratio of 35:1.
Management guidance expansionProlonged Middle East tensions may increase costs for sourcing, logistics, and working capital, with limited ability to pass through.
medium · analyst_questionUS tariffs on Indian pharma could affect innovation-related work; management noted multiple mitigation paths but uncertainty remains.
medium · analyst_questionA ₹176 crore impairment was taken on R&D intangibles due to changed market conditions; similar write-offs may recur.
low · data_observationCDMO revenue remains H2-weighted, causing quarterly volatility; this pattern is expected to persist in FY27.
low · management_commentaryGrowth in tier-1 cities like Mumbai is around 11-14%, potentially constrained by high competition from organized and unorganized players.
medium · analyst_questionWhile current acquisitions are on track, future deals may face quality and integration challenges, as management noted many assets do not meet their standards.
medium · management_commentaryManagement indicated no price hike planned currently, but realization growth partly relies on future price increases, which may not materialize if competitive pressures persist.
low · data_observationWe're currently anticipating revenue growth in the early to mid teens with EBITDA expected to grow faster than revenue supported by operating leverage.
We actually saw our win rate increase last year versus the prior year. And we think that's because of a couple of factors.
We are not looking at a price increase, but as the things progresses during the year, if there is a need for us to do it, we would not hesitate to do it.
We believe a sustainable EBITDA at this point over the next three years of 27 to 28% makes sense for us and if we are able to generate more operating leverage we would like to invest it back in the business.
